ABOUT US

PAEAN Biotechnology a pioneer in mitochondria-based therapeutics, is the first company to develop mitochondria as biopharmaceutical agents to Treat Diseases.

Product

3 Products

Under Development

Managed by a Professional Team Over 20 Years of Experience in Digital Biotechnology

$21M+

R&D and Investment Funds Raised Towards Development & Commercialization of the World's First Mitochondrial Therapy

OUR MISSION

Our mission is to revolutionize healthcare by harnessing the untapped potential of mitochondria.

We are committed to advancing mitochondria-based technologies to develop innovative therapies for rare, chronic, and hard-to-treat diseases—improving quality of life through science-driven breakthroughs.

OUR VALUES

At PAEAN, we are driven by values that shape our science and spirit.

We foster innovation to push the boundaries of biotechnology, embrace collaboration to work across disciplines and partners, harness advanced technology to solve unmet medical needs, and uphold rigor in every process to ensure excellence and trust.

These values are embedded in everything we do—every discovery, every trial, every breakthrough.

Innovative

Collaborative

Technology

Rigorous

OUR TECHNOLOGIES

Applying the unique characteristics of mitochondria and proprietary technology platform, PAEAN is developing a first-in-class mitochondria-based pharmaceutical product that has a large potential to treat various rare diseases and cancer.

MILESTONE

Milestones That Shape Our Journey, From scientific
breakthroughs to clinical progress, we build step by step.

Research Collaboration

Seoul National University Hospital

2018 UNTIL NOW

Pre-series A Funding

Korea Investment Partners with KRW 1.5 B

JUN 2018

Series A Funding

Korea Investment Partners, Hana Ventures, Timefolio with KRW 6 B

JUN 2019

Bridge Funding

Korea Investment Partners, Hana Ventures Timefolio with KRW 4.5 B

JUN 2021

Mitochondria GMP Facility

Jung-gu, Seoul

JUN 2021

PN-101 Phase 1/2a IND Approval

World-first allogenic mitochondria as therapeutic agent

JUN 2021

Research Collaboration

MOU with Soonchunhyang University Medical Center and SIMS

SEP 2021 Until Now

Series B Funding

Daol Investment, Hana Ventures, Timefolio, IMM Investment with KRW 7 B

SEP 2022

Research Collaboration

MOU with YiPSCELL

DEC 2022 Until Now

License for Human Cell Management Business MAR 2025

MAR 2025

Cell Processing Facility Approval

JUL 2025

Our Intellectual Properties

PAEAN protects its innovations through a growing portfolio of patents, including granted and pending filings across Korea, the United States, and other major markets.

0+

International Patent Applications

0+

Korean Patents Granted

0+

Total Global
Filings

OUR PARTNER

We Collaborate with leading research institutions, hospitals, and global investors to Accelerate the Development of next-generation mitochondrial therapies.

1 2 3 4 5